{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:28:49Z","timestamp":1760149729941,"version":"build-2065373602"},"reference-count":99,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The purpose of this study is to investigate the expression of the epithelial membrane proteins (EMP) 1, 2, and 3 in adrenal gland neoplasm and to explore the broader implications of this. Tissue microarrays were constructed for 132 cases of adrenal cortical neoplasms (ACN) (adrenal cortical adenoma (115 cases), and carcinoma (17 cases)) and 189 cases of pheochromocytoma. Immunohistochemical staining was performed to identify EMP 1, 2, and 3, and was compared with clinicopathological parameters. The H-score of EMP 3 (p &lt; 0.001) was higher in pheochromocytoma when compared to that of ACN, and the H-score of EMP 1 (p &lt; 0.001) and EMP 3 (p &lt; 0.001) was higher in adrenal cortical carcinomas when compared to that of adrenal cortical adenomas. A higher EMP 1 H-score was observed in pheochromocytomas with a GAPP score \u22653 (p = 0.018). In univariate analysis, high levels of EMP 1 and EMP 3 expression in ACN were associated with shorter overall survival (p = 0.001). Differences were observed in the expression of EMPs between ACN and pheochromocytoma. EMPs are associated with malignant tumor biology in adrenal cortical neoplasm and pheochromocytoma, suggesting the role of a prognostic and\/or predictive factor for EMPs in adrenal tumor.<\/jats:p>","DOI":"10.3390\/ijms241613016","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:53:31Z","timestamp":1692608011000},"page":"13016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-4064","authenticated-orcid":false,"given":"Yoon Jin","family":"Cha","sequence":"first","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-4709","authenticated-orcid":false,"given":"Ja Seung","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/his.13255","article-title":"Challenges in surgical pathology of adrenocortical tumours","volume":"72","author":"Erickson","year":"2018","journal-title":"Histopathology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MED.0000000000000332","article-title":"Update on adrenocortical carcinoma management and future directions","volume":"24","author":"Varghese","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_3","first-page":"635","article-title":"Current management options for recurrent adrenocortical carcinoma","volume":"6","author":"Glover","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","article-title":"Prognostic parameters of metastatic adrenocortical carcinoma","volume":"92","author":"Antoni","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101415","DOI":"10.1016\/j.beem.2020.101415","article-title":"New perspectives for mitotane treatment of adrenocortical carcinoma","volume":"34","author":"Puglisi","year":"2020","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: Results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase ii clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the javelin solid tumor trial","volume":"6","author":"Hoimes","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 Blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase ii study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The vegf inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"Edgerly","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (osi-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (igf-1r) antibody cixutumumab combined with the mtor inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1245\/s10434-020-08221-2","article-title":"Update on pheochromocytoma and paraganglioma from the sso endocrine and head and neck disease site working group, part 2 of 2: Perioperative management and outcomes of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 world health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CCO.0000000000000589","article-title":"Malignant pheochromocytoma and paraganglioma: Management options","volume":"32","author":"Corssmit","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Chougnet","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-mibg in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.32604\/or.2022.026913","article-title":"Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas","volume":"30","author":"Manta","year":"2022","journal-title":"Oncol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Armaiz-Pena, G., Dahia, P.L.M., Lu, Y., Toledo, R.A., Varghese, J., and Habra, M.A. (2022). Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: Do they work?. Cancers, 14.","DOI":"10.3390\/cancers14030467"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/geno.1996.0482","article-title":"Identification and characterization of a cDNA and the structural gene encoding the mouse epithelial membrane protein-1","volume":"36","author":"Lobsiger","year":"1996","journal-title":"Genomics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbcan.2017.04.004","article-title":"EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer","volume":"1868","author":"Wang","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA)-Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11596-012-1043-1","article-title":"EMP-1 promotes tumorigenesis of nsclc through PI3K\/AKT pathway","volume":"32","author":"Lai","year":"2012","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fu, M., Rao, R., Sudhakar, D., Hogue, C.P., Rutta, Z., Morales, S., Gordon, L.K., Braun, J., Goodglick, L., and Wadehra, M. (2011). Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019945"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1038\/onc.2012.622","article-title":"EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF","volume":"32","author":"Gordon","year":"2013","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.juro.2013.12.001","article-title":"Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: Crosstalk with ErbB2-PI3K-Akt Pathway","volume":"192","author":"Wang","year":"2014","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"34859","DOI":"10.18632\/oncotarget.5414","article-title":"Targeting emp3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K\/Akt pathway","volume":"6","author":"Hsieh","year":"2015","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1167\/iovs.17-22454","article-title":"Icg-001 exerts potent anticancer activity against uveal melanoma cells","volume":"59","author":"Kaochar","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s13277-013-1416-5","article-title":"EMP1 inhibits nasopharyngeal cancer cell growth and metastasis through induction apoptosis and angiogenesis","volume":"35","author":"Sun","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3892\/ijo.2014.2488","article-title":"Association of EMP1 with gastric carcinoma invasion, survival and prognosis","volume":"45","author":"Sun","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.3748\/wjg.v20.i14.4001","article-title":"Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma","volume":"20","author":"Sun","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1535-7163.MCT-13-0199","article-title":"Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer","volume":"13","author":"Fu","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-10-0368","article-title":"Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer","volume":"16","author":"Fu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/onc.2017.142","article-title":"EMP2 is a novel therapeutic target for endometrial cancer stem cells","volume":"36","author":"Kiyohara","year":"2017","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1010428317695972","DOI":"10.1177\/1010428317695972","article-title":"EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma","volume":"39","author":"Tang","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ajpath.2013.05.015","article-title":"Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract","volume":"183","author":"Wang","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/sj.onc.1206349","article-title":"cDNA microarray analysis of genes associated with ERBB2 (HER2\/neu) overexpression in human mammary luminal epithelial cells","volume":"22","author":"Mackay","year":"2003","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/geno.1998.5238","article-title":"Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22","volume":"49","author":"Kozak","year":"1998","journal-title":"Genomics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/0008-5472.CAN-04-4283","article-title":"EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma","volume":"65","author":"Alaminos","year":"2005","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.yexmp.2013.07.001","article-title":"Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer","volume":"95","author":"Xue","year":"2013","journal-title":"Exp. Mol. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2008.08.021","article-title":"EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma","volume":"274","author":"Fumoto","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","article-title":"Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors","volume":"26","author":"Aubert","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2559.2009.03423.x","article-title":"Clinicopathological study of a series of 92 adrenocortical carcinomas: From a proposal of simplified diagnostic algorithm to prognostic stratification","volume":"55","author":"Volante","year":"2009","journal-title":"Histopathology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","article-title":"Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas","volume":"46","author":"Pennanen","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","article-title":"Transcriptome analysis reveals that p53 and \u03b2-catenin alterations occur in a group of aggressive adrenocortical cancers","volume":"70","author":"Ragazzon","year":"2010","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/ERC-18-0385","article-title":"Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism","volume":"26","author":"Mouat","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ronchi, C.L., Sbiera, S., Volante, M., Steinhauer, S., Scott-Wild, V., Altieri, B., Kroiss, M., Bala, M., Papotti, M., and Deutschbein, T. (2014). CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105855"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","author":"Volante","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of pass and gapp scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Koh, J.M., Ahn, S.H., Kim, H., Kim, B.J., Sung, T.Y., Kim, Y.H., Hong, S.J., Song, D.E., and Lee, S.H. (2017). Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187398"},{"key":"ref_62","first-page":"484","article-title":"S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas","volume":"115","author":"Unger","year":"1991","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00018-004-4069-0","article-title":"Selection and validation of differentially expressed genes in head and neck cancer","volume":"61","author":"Kuriakose","year":"2004","journal-title":"Cell Mol. Life Sci."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yu, Y.H., Kuo, H.K., and Chang, K.W. (2008). The evolving transcriptome of head and neck squamous cell carcinoma: A systematic review. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003215"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s13277-013-1441-4","article-title":"EMP1, a member of a new family of antiproliferative genes in breast carcinoma","volume":"35","author":"Sun","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5507\/bp.2007.010","article-title":"Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas","volume":"151","author":"Turashvili","year":"2007","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"ref_67","first-page":"889","article-title":"Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes","volume":"61","author":"Hippo","year":"2001","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9440(10)62999-9","article-title":"Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis","volume":"167","author":"Johnson","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7314\/APJCP.2015.16.2.653","article-title":"Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications","volume":"16","author":"Ahmed","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e000900","DOI":"10.1136\/bmjopen-2012-000900","article-title":"Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: A cohort study","volume":"2","author":"Chen","year":"2012","journal-title":"BMJ Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1002\/cncr.25259","article-title":"Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development","volume":"116","author":"Habeeb","year":"2010","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.21957","article-title":"Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome","volume":"107","author":"Wadehra","year":"2006","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000074429","article-title":"Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling","volume":"24","author":"Evtimova","year":"2003","journal-title":"Tumour Biol."},{"key":"ref_74","first-page":"1358","article-title":"Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma","volume":"7","author":"Mora","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/sj.onc.1202759","article-title":"Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype","volume":"18","author":"Smith","year":"1999","journal-title":"Oncogene"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1677\/ERC-08-0072","article-title":"Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma","volume":"15","author":"Margetts","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-3806(99)00092-9","article-title":"Embryonic expression of epithelial membrane protein 1 in early neurons","volume":"116","author":"Wulf","year":"1999","journal-title":"Brain Res. Dev. Brain Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41388-018-0286-0","article-title":"Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1","volume":"37","author":"Shimizu","year":"2018","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/leu.2014.80","article-title":"EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion","volume":"28","author":"Jerchel","year":"2014","journal-title":"Leukemia"},{"key":"ref_80","first-page":"605","article-title":"Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K\/AKT\/mTOR signaling pathway","volume":"42","author":"Miao","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s13277-013-1456-x","article-title":"EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion","volume":"35","author":"Sun","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17142","DOI":"10.1002\/jcb.28974","article-title":"EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44","volume":"120","author":"Wang","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s00268-009-0175-3","article-title":"Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells","volume":"33","author":"Adler","year":"2009","journal-title":"World J. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"22368","DOI":"10.1074\/jbc.M011688200","article-title":"Hypoxia induces the activation of the phosphatidylinositol 3-kinase\/Akt cell survival pathway in PC12 cells: Protective role in apoptosis","volume":"276","author":"Carrera","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1126\/science.7701324","article-title":"Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor","volume":"267","author":"Yao","year":"1995","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1210\/jc.2004-2198","article-title":"AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors","volume":"90","author":"Fassnacht","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"736.e7","DOI":"10.1016\/j.urology.2012.04.032","article-title":"Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas","volume":"80","author":"Chaux","year":"2012","journal-title":"Urology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3346\/jkms.2009.24.1.97","article-title":"EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations","volume":"24","author":"Zhou","year":"2009","journal-title":"J. Korean Med. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11858","DOI":"10.1073\/pnas.0502113102","article-title":"Epithelial membrane protein-1 is a biomarker of gefitinib resistance","volume":"102","author":"Jain","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/modpathol.2010.153","article-title":"Epidermal growth factor receptor in adrenocortical tumors: Analysis of gene sequence, protein expression and correlation with clinical outcome","volume":"23","author":"Adam","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"36235","DOI":"10.18632\/oncotarget.8827","article-title":"Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12672-011-0090-6","article-title":"Targeted therapies for adrenocortical carcinoma: IGF and beyond","volume":"2","author":"Demeure","year":"2011","journal-title":"Horm. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"E2251","DOI":"10.1210\/jc.2012-2669","article-title":"Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis","volume":"97","author":"Ronchi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.3892\/ol.2020.11841","article-title":"High expression of EMP1 predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma","volume":"20","author":"Lin","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cha, Y.J., and Koo, J.S. (2020). Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238466"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1010428317718404","DOI":"10.1177\/1010428317718404","article-title":"EMP3 is induced by TWIST1\/2 and regulates epithelial-to-mesenchymal transition of gastric cancer cells","volume":"39","author":"Han","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1158\/1078-0432.CCR-08-1016","article-title":"Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines","volume":"14","author":"Shimazaki","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4132\/jptm.2015.07.10","article-title":"Membranous insulin-like growth factor-1 receptor (IGF1R) expression is predictive of poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma","volume":"49","author":"Park","year":"2015","journal-title":"J. Pathol. Transl. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/13016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:39Z","timestamp":1760128719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/13016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":99,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241613016"],"URL":"https:\/\/doi.org\/10.3390\/ijms241613016","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,8,21]]}}}